1/31
Practice vocabulary flashcards covering cancer therapies, solid tumors, leukemias, lymphomas, and normal cell regulation based on lecture notes.
Tamoxifen
An estrogen receptor blocker used in cancer therapy.
Herceptin
A monoclonal antibody conjugated to a drug that blocks HER2.
Engineered protein therapy
A cancer therapy modality utilizing antibody-drug conjugates.
PARP inhibitors
Therapeutic agents that disrupt PARP repair of single-strand breaks and release chemotherapy payloads.
Sofosbuvir, ribavirin, and simeprevir
Small molecule inhibitors targeting HCV polymerase and protease.
Recombivax
A VLP-based vaccine developed against HBV.
Moderna personalized mRNA vaccine
An mRNA vaccine designed to recognize patient-specific neoantigens and activate T cells.
Darax unrasib
A small molecule that binds to cyclophilin A, which subsequently binds and inhibits Ras.
Gleevec
A small molecule inhibitor targeting the BCR-ABL fusion kinase.
CAR-T therapy
A treatment using engineered patient T cells that express a synthetic antigen receptor to redirect T cell killing.
Keytruda
A therapeutic antibody that prevents the deactivation of T cells by blocking the PD-1 receptor.
Breast ductal adenocarcinoma
A form of breast cancer originating in ductal epithelial cells, categorized into subtypes including ER+ Lum A, ER+ Lum B, HER2+, and triple-negative.
Hepatocellular carcinoma (HCC)
A liver cancer originating from hepatocytes and caused by HBV (DNA), HCV (RNA), or alcohol/habits, where hepatocytes die due to T cells rather than direct viral action.
Activating CTNNB1 mutations
Mutations located in phosphorylation sites of β-catenin in hepatocellular carcinoma that prevent degradation and constitutively activate Wnt signaling.
Melanoma
A malignancy arising from melanocytes, categorized into subtypes including superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma.
Benign nevus
An early melanocytic lesion characterized by MAPK pathway mutations such as BRAF or NRAS.
Intermediate lesion (Melanoma)
A melanocytic lesion characterized by the addition of TERT mutations to pre-existing MAPK mutations, after which no clear pathway progression exists.
Pancreatic ductal adenocarcinoma (PDAC)
A pancreatic cancer originating from ductal epithelial cells via acinar-to-ductal metaplasia, featuring early and frequent KRAS mutations in 90% of cases.
Lung adenocarcinoma
A lung cancer subtype accounting for 40–50% of cases, originating from alveolar type 2 (AT2) and/or distal airway progenitor cells, with early alterations in EGFR/KRAS and MAP kinase inducers.
Squamous cell lung carcinoma
A lung cancer subtype accounting for 20–30% of cases, originating from basal cells of the proximal airway epithelium, characterized by early TP53 mutations.
Small-cell lung cancer (SCLC)
An aggressive lung malignancy accounting for 10–15% of cases, originating from pulmonary neuroendocrine cells, driven by early loss of both TP53 and RB1.
Large cell lung carcinoma
A lung cancer subtype accounting for <5% of cases with an uncertain cell of origin, displaying no clear pathway to metastasis and a mix of TP53 and KRAS mutations.
Chronic myeloid leukemia (CML)
A leukemia arising from hematopoietic stem cells, driven by a BCR-ABL1 chromosomal translocation providing a constitutive growth signal.
Chronic phase of CML
The initial phase of chronic myeloid leukemia characterized solely by BCR-ABL mutations.
Blast phase of CML
The accelerated, acute phase of chronic myeloid leukemia in which 92% of patients acquire additional genetic mutations.
Acute promyelocytic leukemia (APL)
A leukemia originating from myeloid progenitor cells (promyelocytes) driven by a PML-RARA translocation that causes differentiation arrest while cells remain cycling.
Burkitt lymphoma (BL)
A lymphoma arising from germinal center B cells (centroblasts), driven by MYC activation through Ig-MYC translocation alongside EBV infection, resulting in increased proliferation with high cyclin D.
Follicular lymphoma (FL)
A lymphoma arising from germinal center B cells (centrocytes), driven by the translocation of BCL2 behind a strong Ig promoter, causing BCL2 activation and resistance to apoptosis.
Multiple Myeloma (MM)
A cancer of terminally differentiated B cells (plasma cells) driven by extensive mutations, cyclin D amplification, growth factor amplification, and chromosomal alterations leading to plasma cell expansion and survival.
Phases of normal hepatocyte repair
A three-step regenerative pathway comprising: 1. Prime (prepare to proliferate), 2. Proliferate (repair mediated by Ras, PI3K, Wnt, or YAP/TAZ), and 3. Terminate (cessation of proliferation mediated by TGF-β via p21, p27, and p15).
Melanocyte regulatory signaling
Signaling networks where slowly turning over melanocytes use β-catenin for survival, MAPK (ERK/PI3K) for proliferation, and α-MSH to elevate cAMP for cell survival.
Chimeric Antigen Receptor (CAR) design workflow
A five-stage process comprising: sequencing the target, identifying cell surface proteins, designing a specific receptor, delivering it to T cells, and redirecting T cells against tumors.